COYA (Coya Therapeutics) 5-Year Yield-on-Cost %: 0.00 (As of Sep. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COYA Coya Therapeutics Inc COYA
49 GF Score
Price $4.39
GF Value $6.54
Valuation Significantly Undervalued
View Full Analysis

What is Coya Therapeutics 5-Year Yield-on-Cost %?

Coya Therapeutics COYA -3.10% 49 5-Year Yield-on-Cost % is 0.00 as of Sep. 12, 2026. GuruFocus rates COYA with a GF Score™ of 49/100 and a GF Value™ of $6.54 (Significantly Undervalued). Among 147 Biotechnology companies, Coya Therapeutics ranks worse than 680271.43% on this metric.

Coya Therapeutics's yield on cost for the quarter that ended in Jun. 2026 was 0.00.


The historical rank and industry rank for Coya Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



COYA's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.63
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Coya Therapeutics  (NAS:COYA) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Coya Therapeutics 5-Year Yield-on-Cost % Related Terms


COYA vs ONCY, GUTS, SEER: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Coya Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coya Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coya Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Coya Therapeutics's 5-Year Yield-on-Cost % falls into.


COYA
49GF Score
Coya Therapeutics Inc COYA
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coya Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Coya Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Coya Therapeutics (COYA) has a 5-Year Yield-on-Cost % of 0.00 as of Sep. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Coya Therapeutics and its competitors. According to the industry distribution chart, Coya Therapeutics ranks #999999 out of 147 companies in the Biotechnology industry.
Is Coya Therapeutics' 5-Year Yield-on-Cost % too high?
Coya Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Coya Therapeutics ranks #999999 out of 147 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coya Therapeutics has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coya Therapeutics' 5-Year Yield-on-Cost % compare to ONCY and GUTS?
According to the Biotechnology industry distribution chart, Coya Therapeutics ranks #999999 out of 147 companies for 5-Year Yield-on-Cost %. This places Coya Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.63, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Coya Therapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coya Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coya Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Coya Therapeutics (COYA) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.54, compared to a current price of $4.39 — trading 32.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Coya Therapeutics' overall GF Score™ is 49/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Coya Therapeutics (COYA), the current 5-Year Yield-on-Cost % is 0.00 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coya Therapeutics (COYA) Overvalued in 2026?

Based on GuruFocus' analysis, Coya Therapeutics stock appears to be undervalued. The current stock price of $4.39 is trading 32.9% below its estimated GF Value™ of $6.54. GuruFocus considers Coya Therapeutics to be Significantly Undervalued.

Key valuation signals for COYA:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: $6.54 vs. price of $4.39 (32.9% below fair value)
  • GF Score™: 49/100

No single metric tells the full story. See the COYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Coya Therapeutics Business Description

Address 5850 San Felipe Street, Suite 500, Houston, TX, USA, 77057
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
49GF Score

Get the complete analysis for COYA

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.39
Price
$6.54
GF Value